Microbiome and Cancer Immunotherapy
10.3904/kjm.2021.96.4.312
- Author:
Moonki HONG
1
;
Minkyu JUNG
Author Information
1. Department of Internal Medicine,Yonsei University College of Medicine, Seoul, Korea
- Publication Type:16
- From:Korean Journal of Medicine
2021;96(4):312-317
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Immune checkpoint inhibitors (ICIs) have achieved promising clinical results in cancer treatment over the past decade. However, the efficacy of ICIs is less than 30% in most tumor types, and studies are underway to identify the predictive factors responsive to ICIs. More than 1,000 species of microorganisms live in the human body, and the second human genome project, The Human Microbiome Project, has been conducted to understand human diseases through interactions with microbes. As the microbiome project has progressed, many studies have reported on the association between microorganisms and human diseases, including preclinical and clinical studies on the relationship between ICIs and the microbiome. Therefore, in this manuscript, the relationship between the microbiome and cancer, especially the effectiveness of ICIs, is reviewed.
